LOGIN
THA: Bone resorption of periprosthetic region reduced for up to a year with risedronate
November 2013
THA: Bone resorption of periprosthetic region reduced for up to a year with risedronate
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial
J Bone Joint Surg Am. 2011 Oct 19;93(20):1857-64. doi: 10.2106/JBJS.J.01646Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
73 patients were randomized to determine the effect of a bisphosphonate therapy on bone mineral density (BMD) of the periprosthetic regions following total hip arthroplasty (THA). Patients received either risedronate or a placebo once a week for 6 months, and were followed-up for 24 months postoperatively. Results indicated that bone resorption in the periprosthetic regions was reduced with risedr...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.